Sangamo Therapeutics, Inc. (SGMO) announced U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, the company's gene therapy product candidate for the treatment of Fabry disease. The FDA has agreed that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec. Also, the EMA has granted PRIME eligibility to isaralgagene civaparvovec.
Nathalie Dubois Stringfellow, Chief Development Officer of Sangamo, said: "The alignment on a regulatory pathway that could potentially deliver a new treatment option for Fabry disease patients on an expedited, cost-effective timeline."
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.